Randomized clinical trials and longitudinal observational studies in systemic lupus erythematosus

Consensus on a preliminary core set of outcome domains

Josef S. Smolen, Vibeke Strand, Mario Cardiel, Steven Edworthy, Daniel Furst, Dafna Gladman, Caroline Gordon, David A. Isenberg, John H. Klippel, Michelle Petri, Lee Simon, Peter Tugwell, Frederick Wolfe

Research output: Contribution to journalArticle

Abstract

The OMERACT module on systemic lupus erythematosus (SLE) dealt with the definition of preliminary core sets of outcome domains for randomized clinical trials (RCT) and longitudinal observational studies (LOS). After lectures introducing the problems and addressing the key issues, 6 discussion groups, 3 each for LOS and RCT, discussed and weighted more than a dozen possible items for use as outcome domains. The means of the respective 3 groups were calculated. For both RCT and LOS the same outcome domains received more than 10 of a total maximum of 100 points: disease activity, health related quality of life (HRQOL), damage, and toxicity/adverse events. However, the weights for HRQOL and damage were different for LOS and RCT. A final vote led to the acceptance of these 4 variables as a preliminary core set for outcome in SLE by more than 80% of the participants. This core set will allow for improved design, performance, and evaluation of future studies in SLE. However, a number of domains not included in the core set were regarded as important for further analysis and research.

Original languageEnglish (US)
Pages (from-to)504-507
Number of pages4
JournalJournal of Rheumatology
Volume26
Issue number2
StatePublished - 1999
Externally publishedYes

Fingerprint

Systemic Lupus Erythematosus
Observational Studies
Longitudinal Studies
Randomized Controlled Trials
Quality of Life
Weights and Measures
Research

Keywords

  • Clinical trials
  • Outcome
  • Systemic lupus erythematosus

ASJC Scopus subject areas

  • Rheumatology
  • Immunology

Cite this

Smolen, J. S., Strand, V., Cardiel, M., Edworthy, S., Furst, D., Gladman, D., ... Wolfe, F. (1999). Randomized clinical trials and longitudinal observational studies in systemic lupus erythematosus: Consensus on a preliminary core set of outcome domains. Journal of Rheumatology, 26(2), 504-507.

Randomized clinical trials and longitudinal observational studies in systemic lupus erythematosus : Consensus on a preliminary core set of outcome domains. / Smolen, Josef S.; Strand, Vibeke; Cardiel, Mario; Edworthy, Steven; Furst, Daniel; Gladman, Dafna; Gordon, Caroline; Isenberg, David A.; Klippel, John H.; Petri, Michelle; Simon, Lee; Tugwell, Peter; Wolfe, Frederick.

In: Journal of Rheumatology, Vol. 26, No. 2, 1999, p. 504-507.

Research output: Contribution to journalArticle

Smolen, JS, Strand, V, Cardiel, M, Edworthy, S, Furst, D, Gladman, D, Gordon, C, Isenberg, DA, Klippel, JH, Petri, M, Simon, L, Tugwell, P & Wolfe, F 1999, 'Randomized clinical trials and longitudinal observational studies in systemic lupus erythematosus: Consensus on a preliminary core set of outcome domains', Journal of Rheumatology, vol. 26, no. 2, pp. 504-507.
Smolen, Josef S. ; Strand, Vibeke ; Cardiel, Mario ; Edworthy, Steven ; Furst, Daniel ; Gladman, Dafna ; Gordon, Caroline ; Isenberg, David A. ; Klippel, John H. ; Petri, Michelle ; Simon, Lee ; Tugwell, Peter ; Wolfe, Frederick. / Randomized clinical trials and longitudinal observational studies in systemic lupus erythematosus : Consensus on a preliminary core set of outcome domains. In: Journal of Rheumatology. 1999 ; Vol. 26, No. 2. pp. 504-507.
@article{8bc20383a9284d09b52c7d71634f9248,
title = "Randomized clinical trials and longitudinal observational studies in systemic lupus erythematosus: Consensus on a preliminary core set of outcome domains",
abstract = "The OMERACT module on systemic lupus erythematosus (SLE) dealt with the definition of preliminary core sets of outcome domains for randomized clinical trials (RCT) and longitudinal observational studies (LOS). After lectures introducing the problems and addressing the key issues, 6 discussion groups, 3 each for LOS and RCT, discussed and weighted more than a dozen possible items for use as outcome domains. The means of the respective 3 groups were calculated. For both RCT and LOS the same outcome domains received more than 10 of a total maximum of 100 points: disease activity, health related quality of life (HRQOL), damage, and toxicity/adverse events. However, the weights for HRQOL and damage were different for LOS and RCT. A final vote led to the acceptance of these 4 variables as a preliminary core set for outcome in SLE by more than 80{\%} of the participants. This core set will allow for improved design, performance, and evaluation of future studies in SLE. However, a number of domains not included in the core set were regarded as important for further analysis and research.",
keywords = "Clinical trials, Outcome, Systemic lupus erythematosus",
author = "Smolen, {Josef S.} and Vibeke Strand and Mario Cardiel and Steven Edworthy and Daniel Furst and Dafna Gladman and Caroline Gordon and Isenberg, {David A.} and Klippel, {John H.} and Michelle Petri and Lee Simon and Peter Tugwell and Frederick Wolfe",
year = "1999",
language = "English (US)",
volume = "26",
pages = "504--507",
journal = "Journal of Rheumatology",
issn = "0315-162X",
publisher = "Journal of Rheumatology",
number = "2",

}

TY - JOUR

T1 - Randomized clinical trials and longitudinal observational studies in systemic lupus erythematosus

T2 - Consensus on a preliminary core set of outcome domains

AU - Smolen, Josef S.

AU - Strand, Vibeke

AU - Cardiel, Mario

AU - Edworthy, Steven

AU - Furst, Daniel

AU - Gladman, Dafna

AU - Gordon, Caroline

AU - Isenberg, David A.

AU - Klippel, John H.

AU - Petri, Michelle

AU - Simon, Lee

AU - Tugwell, Peter

AU - Wolfe, Frederick

PY - 1999

Y1 - 1999

N2 - The OMERACT module on systemic lupus erythematosus (SLE) dealt with the definition of preliminary core sets of outcome domains for randomized clinical trials (RCT) and longitudinal observational studies (LOS). After lectures introducing the problems and addressing the key issues, 6 discussion groups, 3 each for LOS and RCT, discussed and weighted more than a dozen possible items for use as outcome domains. The means of the respective 3 groups were calculated. For both RCT and LOS the same outcome domains received more than 10 of a total maximum of 100 points: disease activity, health related quality of life (HRQOL), damage, and toxicity/adverse events. However, the weights for HRQOL and damage were different for LOS and RCT. A final vote led to the acceptance of these 4 variables as a preliminary core set for outcome in SLE by more than 80% of the participants. This core set will allow for improved design, performance, and evaluation of future studies in SLE. However, a number of domains not included in the core set were regarded as important for further analysis and research.

AB - The OMERACT module on systemic lupus erythematosus (SLE) dealt with the definition of preliminary core sets of outcome domains for randomized clinical trials (RCT) and longitudinal observational studies (LOS). After lectures introducing the problems and addressing the key issues, 6 discussion groups, 3 each for LOS and RCT, discussed and weighted more than a dozen possible items for use as outcome domains. The means of the respective 3 groups were calculated. For both RCT and LOS the same outcome domains received more than 10 of a total maximum of 100 points: disease activity, health related quality of life (HRQOL), damage, and toxicity/adverse events. However, the weights for HRQOL and damage were different for LOS and RCT. A final vote led to the acceptance of these 4 variables as a preliminary core set for outcome in SLE by more than 80% of the participants. This core set will allow for improved design, performance, and evaluation of future studies in SLE. However, a number of domains not included in the core set were regarded as important for further analysis and research.

KW - Clinical trials

KW - Outcome

KW - Systemic lupus erythematosus

UR - http://www.scopus.com/inward/record.url?scp=0032926068&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032926068&partnerID=8YFLogxK

M3 - Article

VL - 26

SP - 504

EP - 507

JO - Journal of Rheumatology

JF - Journal of Rheumatology

SN - 0315-162X

IS - 2

ER -